215 related articles for article (PubMed ID: 2225025)
1. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
3. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
S Afr Med J; 1996 Aug; 86(8):960-5. PubMed ID: 8823423
[TBL] [Abstract][Full Text] [Related]
5. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
Am Rev Respir Dis; 1979 Apr; 119(4):579-85. PubMed ID: 375787
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J
Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098
[TBL] [Abstract][Full Text] [Related]
8. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
Tubercle; 1976 Jun; 57(2):81-95. PubMed ID: 134476
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong.
Tubercle; 1975 Jun; 56(2):81-96. PubMed ID: 1103400
[TBL] [Abstract][Full Text] [Related]
10. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study.
Tubercle; 1986 Mar; 67(1):5-15. PubMed ID: 3521015
[TBL] [Abstract][Full Text] [Related]
11. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Girling DJ
Tubercle; 1978 Mar; 59(1):13-32. PubMed ID: 345572
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
14. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study.
Am Rev Respir Dis; 1976 Sep; 114(3):471-5. PubMed ID: 788570
[TBL] [Abstract][Full Text] [Related]
15. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
16. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
[TBL] [Abstract][Full Text] [Related]
17. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet.
Cowie RL; Brink BA
S Afr Med J; 1990 Apr; 77(8):390-1. PubMed ID: 2184527
[TBL] [Abstract][Full Text] [Related]
18. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
Am Rev Respir Dis; 1981 Feb; 123(2):165-70. PubMed ID: 7015933
[TBL] [Abstract][Full Text] [Related]
19. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
Grönhagen-Riska C; Hellstrom PE; Fröseth B
Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
[TBL] [Abstract][Full Text] [Related]
20. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study.
Tubercle; 1980 Jun; 61(2):59-69. PubMed ID: 6159711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
